Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R K Russell

Showing results (41-50 of 53) with videos related to

Pageof 6
Sort By:
The Journal of Pediatrics|February 20, 2007
The contribution of the DLG5 113A variant in early-onset inflammatory bowel diseaseR K Russell, H E Drummond, E R Nimmo, et al.
Inflammatory Bowel Diseases|March 8, 2022
Comparing Effectiveness of a Generic Oral Nutritional Supplement With Specialized Formula in the Treatment of Active Pediatric Crohn's DiseaseR Dawson, D I F Wands, M Logan, et al.
Gut|February 14, 2006
Analysis of the influence of OCTN1/2 variants within the IBD5 locus on disease susceptibility and growth indices in early onset inflammatory bowel diseaseR K Russell, H E Drummond, E R Nimmo, et al.
Journal of Pediatric Gastroenterology and Nutrition|January 31, 2009
Anti-Saccharomyces cerevisiae antibodies status is associated with oral involvement and disease severity in Crohn diseaseR K Russell, B Ip, M C Aldhous, et al.
Gut|March 6, 2007
IL23R Arg381Gln is associated with childhood onset inflammatory bowel disease in ScotlandJ Van Limbergen, R K Russell, E R Nimmo, et al.
Inflammatory Bowel Diseases|May 2, 2009
Filaggrin loss-of-function variants are associated with atopic comorbidity in pediatric inflammatory bowel diseaseJ Van Limbergen, R K Russell, E R Nimmo, et al.
Inflammatory Bowel Diseases|December 20, 2007
Autophagy gene ATG16L1 influences susceptibility and disease location but not childhood-onset in Crohn's disease in Northern EuropeJ Van Limbergen, R K Russell, E R Nimmo, et al.
Alimentary Pharmacology & Therapeutics|February 3, 2009
Efficacy and complications of adalimumab treatment for medically-refractory Crohn's disease: analysis of nationwide experience in Scotland (2004-2008)G T Ho, A Mowat, L Potts, et al.
Journal of Medicinal Chemistry|July 31, 1998
Substituted salicylanilides as inhibitors of two-component regulatory systems in bacteriaM J Macielag, J P Demers, S A Fraga-Spano, et al.
Inflammatory Bowel Diseases|February 8, 2007
Contribution of the NOD1/CARD4 insertion/deletion polymorphism +32656 to inflammatory bowel disease in Northern EuropeJ Van Limbergen, R K Russell, E R Nimmo, et al.
Pageof 6

Showing results (41-50 of 53) with videos related to

Sort By:
Pageof 6
The Journal of Pediatrics|February 20, 2007
The contribution of the DLG5 113A variant in early-onset inflammatory bowel diseaseR K Russell, H E Drummond, E R Nimmo, et al.
Inflammatory Bowel Diseases|March 8, 2022
Comparing Effectiveness of a Generic Oral Nutritional Supplement With Specialized Formula in the Treatment of Active Pediatric Crohn's DiseaseR Dawson, D I F Wands, M Logan, et al.
Gut|February 14, 2006
Analysis of the influence of OCTN1/2 variants within the IBD5 locus on disease susceptibility and growth indices in early onset inflammatory bowel diseaseR K Russell, H E Drummond, E R Nimmo, et al.
Journal of Pediatric Gastroenterology and Nutrition|January 31, 2009
Anti-Saccharomyces cerevisiae antibodies status is associated with oral involvement and disease severity in Crohn diseaseR K Russell, B Ip, M C Aldhous, et al.
Gut|March 6, 2007
IL23R Arg381Gln is associated with childhood onset inflammatory bowel disease in ScotlandJ Van Limbergen, R K Russell, E R Nimmo, et al.
Inflammatory Bowel Diseases|May 2, 2009
Filaggrin loss-of-function variants are associated with atopic comorbidity in pediatric inflammatory bowel diseaseJ Van Limbergen, R K Russell, E R Nimmo, et al.
Inflammatory Bowel Diseases|December 20, 2007
Autophagy gene ATG16L1 influences susceptibility and disease location but not childhood-onset in Crohn's disease in Northern EuropeJ Van Limbergen, R K Russell, E R Nimmo, et al.
Alimentary Pharmacology & Therapeutics|February 3, 2009
Efficacy and complications of adalimumab treatment for medically-refractory Crohn's disease: analysis of nationwide experience in Scotland (2004-2008)G T Ho, A Mowat, L Potts, et al.
Journal of Medicinal Chemistry|July 31, 1998
Substituted salicylanilides as inhibitors of two-component regulatory systems in bacteriaM J Macielag, J P Demers, S A Fraga-Spano, et al.
Inflammatory Bowel Diseases|February 8, 2007
Contribution of the NOD1/CARD4 insertion/deletion polymorphism +32656 to inflammatory bowel disease in Northern EuropeJ Van Limbergen, R K Russell, E R Nimmo, et al.
Pageof 6